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I. METHOD OF ESTIMATION OF PITUITARY GONADOTROPHINS IN URINE
The method described by Loraine & Brown (1959) (Strong 1958; Loraine et al., in press).
Gonadotrophin assays were performed in 32 patients before adrenalectomy and oophorectomy; a total of 104 observations was made. It was found that, although the mean gonadotrophin excretion in the group subsequently de¬ signated "remission" was higher than that in the group designated "no remission", the difference between these values was not significant (P = 0.2-0.1). Accordingly, it was concluded that, under the conditions of the investi¬ gation, such estimations were of little or no value in predicting the response of patients to this form of treatment.
Gonadotrophin excretion was studied in 37 patients following bilateral adrenalectomy and oophorectomy; a total of 96 observations was made. It was found that the mean gonadotrophin excretion in the group designated "remission" was considerably higher than that in the group designated "no remission". The difference between these mean values was highly significant (P < 0.001). Possible reasons for the differing excretion patterns following adrenalectomy will be discussed.
III. HORMONE ASSAYS DURING THE MENSTRUAL CYCLE
Two subjects will be considered. (a) Hormone excretion in normally menstruating women A study of the urinary excretion of oestrogens, pregnanediol and pituitary gonadotrophins has been made by Brown, Klopper & Loraine ( 1958) . Oestrogens were measured by the method of Brown (1955) and pregnanediol by the method of Klopper, Michie & Brown (1955) .Most subjects kept basal temperature records and where possible, any change in basal temperature was correlated with the pattern of hormone excretion.
In none of the subjects studied did the urinary gonadotrophin peak at midcycle precede the oestrogen peak. Indeed, in some individuals the gonado¬ trophin peak occurred several days after the first oestrogen peak. In a propor¬ tion of subjects a gonadotrophin peak at midcycle was not observed although all the other evidence indicated that ovulation had occurred.
When gonadotrophin assays were conducted by the mouse uterus and hypophysectomised rat prostate tests, the results obtained agreed very closely at all stages of the cycle. This finding is compatible with the view that, through¬ out the cycle, a single gonadotrophin with two activities is being excreted.
The fact that ICSH activity can usually be found in urine at all stages of the menstrual cycle conflicts with the generally accepted hypothesis that this hormone is secreted only at the time of ovulation and in the early luteal phase of the cycle.
One individual was artificially inseminated on the day of the expected midcycle oestrogen peak and became pregnant during the period of study. The first indication that conception had occurred was a sharp rise in urinary gonadotrophin excretion 9 days after insemination. It should be noted that, in this subject, previous inseminations performed at the time of the rise in basal temperature had been unsuccessful.
(b) The effect of norethisterone acetate on hormone excretion
The effect of this drug on the excretion of oestrogens, pregnanediol and gonadotrophins was studied in patients with dysmenorrhoea and with pre¬ menstrual tension (Brown, Fotherby & Loraine, unpubl.) . In a subject with dysmenorrhoea norethisterone acetate, in a dosage of 6 mg/d orally from the 5th to the 25th day of the cycle, abolished the "luteal peak" of oestrogen excretion and prevented the luteal phase rise in urinary pregnanediol; the "midcycle peak" of oestrogen excretion was not affected. With a dosage of 12 mg/d both peaks of oestrogen excretion were abolished, the luteal phase rise in pregnanediol did not occur, and it was reasonable to conclude that ovulation had been inhibited. Similar results using a dosage of norethisterone of 12 mg/d were obtained in a patient with premenstrual tension.
Throughout the period of administration of the drug, urinary gonadotrophin excretion continued and, in some individuals, the levels tended to rise. This finding suggests that norethisterone acetate exerts its effect by a direct action on the ovary and not, as was previously supposed, by inhibiting the secretion of gonadotrophins by the anterior lobe of the pituitary gland.
